These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3315283)

  • 61. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
    Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
    Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group.
    Ravelli A; Gerloni V; Corona F; Falcini F; Lepore L; De Sanctis R; Zulian F; Buoncompagni A; Sardella ML; Strano CG; Alessio M; Fantini F; Bardare M; Martini A
    Clin Exp Rheumatol; 1998; 16(2):181-3. PubMed ID: 9536397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
    Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
    Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion.
    Creinin MD; Krohn MA
    Am J Obstet Gynecol; 1997 Dec; 177(6):1444-9. PubMed ID: 9423749
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effect of nitrogen mustard to maintain remission of acute lymphoblastic leukemia in children].
    Silva Sosa M; Sedas T; Ajuria E
    Bol Med Hosp Infant Mex; 1974; 31(4):785-98. PubMed ID: 4529618
    [No Abstract]   [Full Text] [Related]  

  • 66. [Which is the best methotrexate schedule for maintenance therapy of childhood ALL? A randomized study].
    Wehinger H; Gutjahr P; Hofweber K; Imm W; Jacobi H; Jobke A; Langermann HJ; Lasson U; Nawrath H; Nessler G; Schenck W; Streitberger W
    Klin Padiatr; 1982; 194(4):214-8. PubMed ID: 6752558
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bone-marrow toxicity of methotrexate: a reassessment.
    Douglas ID; Price LA
    Br J Haematol; 1973 May; 24(5):625-31. PubMed ID: 4514552
    [No Abstract]   [Full Text] [Related]  

  • 68. Prospective study of central nervous system changes in children with acute lymphoblastic leukemia receiving two different methods of central nervous system prophylaxis.
    Ochs J; Parvey LS; Mulhern R
    Neurotoxicology; 1986; 7(2):217-26. PubMed ID: 2431364
    [No Abstract]   [Full Text] [Related]  

  • 69. Rational use of methotrexate in maintenance therapy of childhood acute lymphoblastic leukemia.
    Wang ZH; Yu ZL
    Chin Med J (Engl); 1992 Feb; 105(2):147-52. PubMed ID: 1597076
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The treatment of childhood acute lymphoblastic leukemia based on the pharmacokinetics of methotrexate in serum and cerebrospinal fluid.
    Muchi H; Ijima H; Karube T
    Nihon Ketsueki Gakkai Zasshi; 1985 Sep; 48(6):1397-408. PubMed ID: 3867213
    [No Abstract]   [Full Text] [Related]  

  • 71. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.
    Godfrey C; Sweeney K; Miller K; Hamilton R; Kremer J
    Br J Clin Pharmacol; 1998 Oct; 46(4):369-76. PubMed ID: 9803986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood.
    Br Med J; 1971 Oct; 4(5781):189-94. PubMed ID: 4940157
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
    Balis FM; Savitch JL; Bleyer WA; Reaman GH; Poplack DG
    J Clin Oncol; 1985 Apr; 3(4):485-9. PubMed ID: 3856631
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse.
    Morse M; Savitch J; Balis F; Miser J; Feusner J; Reaman G; Poplack D; Bleyer A
    J Clin Oncol; 1985 Jan; 3(1):19-24. PubMed ID: 3855310
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of acute lymphoblastic leukemia in childreq with "prophylactic" intrathecal methotrexate and intensive systemic chemotherapy.
    Haghbin M; Tan CT; Clarkson BD; Miké V; Burchenal JH; Murphy ML
    Cancer Res; 1975 Mar; 35(3):807-11. PubMed ID: 1054287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intermediate-dose methotrexate in the treatment of childhood acute lymphocytic leukaemia: lack of benefit during maintenance therapy following intensive induction therapy.
    Janka-Schaub GE; Winkler K; Jürgens H; Goebel U; Gutjahr P; Spaar HJ
    Eur J Pediatr; 1986 Apr; 145(1-2):14-7. PubMed ID: 3525176
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.
    Schrøder H; Clausen N; Ostergaard E; Pressler T
    Cancer Chemother Pharmacol; 1986; 16(2):190-3. PubMed ID: 3456283
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Methotrexate levels in the blood and cerebrospinal fluid in children with acute lymphoid leukemia treated with medium doses of methotrexate].
    Borsi J; Koós R; Révész T; Schuler D
    Orv Hetil; 1984 Oct; 125(44):2667-8, 2671-3. PubMed ID: 6387586
    [No Abstract]   [Full Text] [Related]  

  • 79. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group.
    Miller DR; Leikin S; Albo V; Sather H; Karon M; Hammond D
    Cancer; 1983 Mar; 51(6):1041-9. PubMed ID: 6336986
    [No Abstract]   [Full Text] [Related]  

  • 80. The pharmacology of orally administered chemotherapy. A reappraisal.
    Poplack DG; Balis FM; Zimm S
    Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.